<p>The Serum Institute of India, which produces the AstraZeneca Covid-19 vaccine, will resume small exports via the global vaccine-sharing platform COVAX this month and raise it substantially by January, its head told The Telegraph.</p>.<p><strong>Also read:<a href="https://www.deccanherald.com/national/dcgi-allows-serum-institute-to-enrol-7-11-year-olds-in-covid-19-vaccine-trial-1035040.html" target="_blank"> DCGI allows Serum Institute to enrol 7-11-year-olds in Covid-19 vaccine trial</a></strong></p>.<p>"Our exports to COVAX will recommence again in October, initially these supplies will be small but by January 2022, once we have satisfied domestic demands – people forget that India is still a lower-middle income country – we will see large volumes go to COVAX," Chief Executive Adar Poonawalla said </p>
<p>The Serum Institute of India, which produces the AstraZeneca Covid-19 vaccine, will resume small exports via the global vaccine-sharing platform COVAX this month and raise it substantially by January, its head told The Telegraph.</p>.<p><strong>Also read:<a href="https://www.deccanherald.com/national/dcgi-allows-serum-institute-to-enrol-7-11-year-olds-in-covid-19-vaccine-trial-1035040.html" target="_blank"> DCGI allows Serum Institute to enrol 7-11-year-olds in Covid-19 vaccine trial</a></strong></p>.<p>"Our exports to COVAX will recommence again in October, initially these supplies will be small but by January 2022, once we have satisfied domestic demands – people forget that India is still a lower-middle income country – we will see large volumes go to COVAX," Chief Executive Adar Poonawalla said </p>